Home › Funds › Fairbanks Capital Management, Inc. › BSX
Fairbanks Capital Management, Inc. position in BSX
BOSTON SCIENTIFIC CORP · Health Care
Fairbanks Capital Management, Inc. reported holding 23,557 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$1.0M, representing 0.62% of its reported portfolio and ranking #38 among its reported holdings. Fairbanks Capital Management, Inc. has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Fairbanks Capital Management, Inc.'s BSX position evolved
Fairbanks Capital Management, Inc. first disclosed a stake in BSX in Q3 2023 at 26,142 shares (US$1.4M). The position peaked in Q2 2025 at 25,693 shares, worth US$2.8M. Across 13 filings, Fairbanks Capital Management, Inc. increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 23,557 shares valued at US$1.0M — a reduction of -951 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 26.14K | $1.38M | New |
| Q4 2023 | 27.59K | $1.59M | Add |
| Q1 2024 | 27.17K | $1.86M | Reduce |
| Q2 2024 | 27.82K | $2.14M | Add |
| Q3 2024 | 29.47K | $2.47M | Add |
| Q4 2024 | 30.22K | $2.70M | Add |
| Q1 2025 | 24.08K | $2.43M | Reduce |
| Q2 2025 | 25.69K | $2.76M | Add |
| Q3 2025 | 25.71K | $2.51M | Hold |
| Q4 2025 | 25.47K | $2.43M | Reduce |
| Q1 2026 | 24.87K | $1.56M | Reduce |
| Q2 2026 | 24.51K | $1.05M | Reduce |
| Q3 2026 | 23.56K | $1.03M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 18 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- PRIMECAP MANAGEMENT CO/CA/ 58.62M sh · $2.56B · Q3 2026
- MFS Investment Management 43.05M sh · $2.29B · Q3 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
- Arrowstreet Capital 23.29M sh · $994.18M · Q2 2026
More on Fairbanks Capital Management, Inc.
FAQ
How long has Fairbanks Capital Management, Inc. held BSX?
Fairbanks Capital Management, Inc. has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Fairbanks Capital Management, Inc.'s current position in BSX?
As of Q3 2026, Fairbanks Capital Management, Inc. holds 23.56K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $1.03M, representing 0.62% of its reported portfolio and ranking #38.
Has Fairbanks Capital Management, Inc. been buying or selling BSX?
In the latest 13F filing (Q3 2026), Fairbanks Capital Management, Inc. reduced its position in BSX. The position peaked in Q2 2025 at 25.69K shares.
Which other funds hold BSX?
Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, D. E. Shaw & Co, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.